BCL11A and Schnyder corneal dystrophy: In addition to targeting HbF repressors such as BCL11A, another gene editing strategy to treat SCD uses gene editing technology to induce deletion of the β‐globin gene cluster with rare naturally occurring β‐globin mutations in patients with SCD, resulting in HPFH‐related or similar mutations to improve SCD clinical severity.236